PA8626201A1 - Conjugados de caliqueamicina - Google Patents

Conjugados de caliqueamicina

Info

Publication number
PA8626201A1
PA8626201A1 PA20058626201A PA8626201A PA8626201A1 PA 8626201 A1 PA8626201 A1 PA 8626201A1 PA 20058626201 A PA20058626201 A PA 20058626201A PA 8626201 A PA8626201 A PA 8626201A PA 8626201 A1 PA8626201 A1 PA 8626201A1
Authority
PA
Panama
Prior art keywords
conjugates
caliqueamycin
pharmaco
lewis
compositions
Prior art date
Application number
PA20058626201A
Other languages
English (en)
Inventor
Arthur Kunz
Justin Keith Moran
Joseph Thomas Rubino
Neera Jain
Erwin Raymond Arsene Boghaert
Philis Ross Hamann
Mark Edward Ruppen
Nitin Krishanaji Damle
Eugene Vidunas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8626201A1 publication Critical patent/PA8626201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE DESCRIBEN ANTICUERPOS ANTI-LEWIS Y. SE DESCRIBEN METODOS PARA PREPARAR CONJUGADOS DE FARMACO/VEHICULO CITOTOXICOS MONOMERICOS CON UNA CARGA DE FARMACO SIGNIFICATIVAMENTE MAS ELEVADA QUE EN LOS PROCEDIMIENTOS INFORMADOS ANTERIORMENTE Y CON MENOR AGREGACION Y FRACCION DE CONJUGACION BAJA (LCF). TAMBIEN SE DESCRIBEN CONJUGADOS CITOTOXICO DE DERIVADO DE FARMACO/ANTICUERPO, COMPOSICIONES QUE COMPRENDEN LOS CONJUGADOS Y USOS DE LOS CONJUGADOS. ESPECIFICAMENTE, TAMBIEN SE DESCRIBEN CONJUGADOS DE DERIVADO MONOMERICO DE CALIQUEAMICINA/ANTICUERPO ANTI-LEWIS Y, COMPOSICIONES QUE COMPRENDEN LOS CONJUGADOS Y USOS DE LOS CONJUGADOS.
PA20058626201A 2004-03-15 2005-03-15 Conjugados de caliqueamicina PA8626201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55311204P 2004-03-15 2004-03-15

Publications (1)

Publication Number Publication Date
PA8626201A1 true PA8626201A1 (es) 2006-06-02

Family

ID=34962653

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058626201A PA8626201A1 (es) 2004-03-15 2005-03-15 Conjugados de caliqueamicina

Country Status (22)

Country Link
US (4) US20070190060A1 (es)
EP (3) EP1740216A2 (es)
JP (2) JP2007529535A (es)
KR (1) KR20060130737A (es)
CN (2) CN1997397A (es)
AR (1) AR048098A1 (es)
AU (3) AU2005222634A1 (es)
BR (2) BRPI0508860A (es)
CA (3) CA2558737A1 (es)
CR (1) CR8620A (es)
EC (1) ECSP066851A (es)
GT (1) GT200500054A (es)
IL (1) IL177842A0 (es)
MX (2) MXPA06010555A (es)
NO (1) NO20064128L (es)
PA (1) PA8626201A1 (es)
PE (1) PE20060077A1 (es)
RU (1) RU2006131599A (es)
SV (1) SV2006002050A (es)
TW (1) TW200539855A (es)
WO (3) WO2005089809A2 (es)
ZA (1) ZA200607705B (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060817A1 (es) * 2004-09-10 2006-10-10 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007067602A1 (en) * 2005-12-06 2007-06-14 Wyeth Interleukin-11 compositions and methods of use
KR101443752B1 (ko) 2006-03-10 2014-09-26 와이어쓰 엘엘씨 항-５ｔ４ 항체 및 이의 용도
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
ATE462442T1 (de) * 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
CN102905727B (zh) * 2009-10-30 2016-12-07 詹森生物科技公司 Il-17a拮抗剂
WO2012065161A2 (en) 2010-11-12 2012-05-18 Scott & White Healthcare Antibodies to tumor endothelial marker 8
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
KR101921068B1 (ko) 2011-05-08 2018-11-22 주식회사 레고켐 바이오사이언스 단백질-활성제 접합체 및 이의 제조 방법
RU2011132483A (ru) * 2011-08-02 2013-02-10 Елена Александровна Моренко Биологически активный продукт для применения в ветеринарии и животноводстве, способ его получения и способы повышения выживаемости, стимуляции роста, иммуностимуляции и повышения общей неспецифической резистентности организма сельскохозяйственных животных
RU2713121C2 (ru) 2012-04-27 2020-02-03 Сайтомкс Терапьютикс, Инк. Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
CN105188766B (zh) 2013-03-15 2019-07-12 瑞泽恩制药公司 生物活性分子、其偶联物及治疗用途
BR112016004023A2 (pt) 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
EP3273998B1 (en) 2015-03-27 2019-09-04 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
EP3313389A1 (en) * 2015-06-29 2018-05-02 William Marsh Rice University Total synthesis of shishijimicin a and analogs thereof
MX2017017117A (es) 2015-07-06 2018-03-06 Regeneron Pharma Moleculas multiespecificas de union a antigenos y usos de estas.
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
JP6949732B2 (ja) 2015-11-25 2021-10-13 レゴケム バイオサイエンシズ， インク．Ｌｅｇｏｃｈｅｍ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自壊性基を含む複合体及びそれに関連した方法
DK3380525T3 (da) 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
CA3007644A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
MA43094B1 (fr) 2016-01-25 2020-10-28 Regeneron Pharma Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
CN105726527B (zh) * 2016-03-25 2018-05-11 苏州大学 小分子化合物的用途及其组合物
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
CA3037732A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
RS63660B1 (sr) 2016-09-23 2022-11-30 Regeneron Pharma Anti-muc16 (mucin 16) antitela
US10711032B2 (en) 2016-11-08 2020-07-14 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
KR102085798B1 (ko) 2016-12-28 2020-03-06 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
MA47392B1 (fr) 2017-05-18 2021-09-30 Regeneron Pharma Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
AU2018270784B2 (en) 2017-05-18 2024-05-16 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
SG11202006510XA (en) 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
JP7328990B2 (ja) 2018-04-30 2023-08-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
US20210079109A1 (en) 2018-05-17 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
EP3858863A1 (en) * 2018-05-30 2021-08-04 AbbVie Stemcentrx LLC Anti-sez6 antibody drug conjugates and methods of use
EA202191430A1 (ru) 2018-11-20 2021-11-29 Регенерон Фармасьютикалз, Инк. Производные бис-октагидрофенантренкарбоксамида и их белковые конъюгаты
CN118027137A (zh) 2018-12-21 2024-05-14 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
WO2020132483A1 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Rifamycin analogs and antibody-drug conjugates thereof
SG11202107212QA (en) 2019-01-08 2021-07-29 Regeneron Pharma Traceless linkers and protein-conjugates thereof
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
US20220040319A1 (en) 2019-02-21 2022-02-10 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
US20220226496A1 (en) 2019-05-02 2022-07-21 Legochem Biosciences, Inc. Ligand-drug conjugate including linker having tris structure
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
CN115348874A (zh) 2020-01-24 2022-11-15 里珍纳龙药品有限公司 蛋白质-抗病毒化合物偶联物
IL295312A (en) 2020-02-28 2022-10-01 Regeneron Pharma Bispecific antigen binding molecules that bind her2 and methods of using them
WO2021211984A1 (en) 2020-04-16 2021-10-21 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
CN115867563A (zh) 2020-06-24 2023-03-28 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
WO2022015656A1 (en) 2020-07-13 2022-01-20 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
AU2021338875A1 (en) * 2020-09-14 2023-02-23 Amgen Inc. Method of making lyophilized protein formulations
MX2023002974A (es) 2020-09-14 2023-05-25 Regeneron Pharma Conjugados de anticuerpo-farmaco que comprenden peptidomimeticos glp1 y usos de los mismos.
CA3190569A1 (en) 2020-10-22 2022-04-28 Christopher Daly Anti-fgfr2 antibodies and methods of use thereof
EP4376895A2 (en) 2021-07-28 2024-06-05 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
US20230414775A1 (en) 2021-12-29 2023-12-28 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
US20230277682A1 (en) 2022-01-14 2023-09-07 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof
KR20230132640A (ko) 2022-03-04 2023-09-15 앱티스 주식회사 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법
US20230330254A1 (en) 2022-03-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereof
US20240218011A1 (en) 2022-07-21 2024-07-04 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024118785A2 (en) 2022-11-30 2024-06-06 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
US20240269308A1 (en) 2022-12-21 2024-08-15 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2024168199A1 (en) 2023-02-09 2024-08-15 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates via inverse electron demand diels-alder reactions

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5822085B2 (ja) * 1977-07-19 1983-05-06 株式会社ミドリ十字 静注用ガンマ・グロブリン製剤
US4675187A (en) * 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4554162A (en) * 1984-05-04 1985-11-19 Warner-Lambert Company CL-1724 Antibiotic compounds, their production and use
US4539203A (en) * 1984-11-13 1985-09-03 Warner-Lambert Company CL-1577D And CL-1577E antibiotic/antitumor compounds, their production and use
US4970198A (en) * 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5108912A (en) * 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5037651A (en) * 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5182192A (en) * 1987-03-27 1993-01-26 The Wistar Institute Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
US4837206A (en) * 1987-04-29 1989-06-06 Bristol-Myers Company Esperamicin derivatives
US5053394A (en) * 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
JPH01146826A (ja) * 1987-12-03 1989-06-08 Nippon Kayaku Co Ltd 白金化合物の凍結乾燥製剤
IL94872A (en) * 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
EP0528767B1 (en) * 1991-08-21 2000-01-12 Novartis AG Antibody derivatives
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
JP3687993B2 (ja) * 1994-06-24 2005-08-24 シスメックス株式会社 インシュリン標準液
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997013529A1 (en) * 1995-10-13 1997-04-17 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment
DK2180007T4 (da) * 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
WO2002034790A1 (en) * 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
NZ592087A (en) * 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CN102180944A (zh) * 2001-10-10 2011-09-14 诺和诺德公司 肽的重构和糖缀合
EP2371392B1 (en) * 2002-05-02 2015-07-08 Wyeth Holdings LLC Calicheamicin derivative-carrier conjugates
KR101292000B1 (ko) * 2003-01-22 2013-08-01 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이증가된 항체를 생성하기 위한 이의 용도
PE20060817A1 (es) * 2004-09-10 2006-10-10 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina

Also Published As

Publication number Publication date
US20060002942A1 (en) 2006-01-05
CN1997397A (zh) 2007-07-11
ZA200607705B (en) 2008-09-25
GT200500054A (es) 2005-10-31
WO2005089809A3 (en) 2006-05-04
TW200539855A (en) 2005-12-16
WO2005089809A2 (en) 2005-09-29
KR20060130737A (ko) 2006-12-19
JP2007529535A (ja) 2007-10-25
JP2007529536A (ja) 2007-10-25
MXPA06010555A (es) 2007-03-26
SV2006002050A (es) 2006-02-15
US20070213511A1 (en) 2007-09-13
CA2559658A1 (en) 2005-09-29
EP1725264A2 (en) 2006-11-29
IL177842A0 (en) 2006-12-31
ECSP066851A (es) 2006-11-24
EP1740216A2 (en) 2007-01-10
MXPA06010556A (es) 2007-03-23
CA2558737A1 (en) 2005-09-29
AU2005222635A1 (en) 2005-09-29
CN1997398A (zh) 2007-07-11
US20090105461A1 (en) 2009-04-23
AR048098A1 (es) 2006-03-29
AU2005222633A1 (en) 2005-09-29
NO20064128L (no) 2006-10-05
US20070190060A1 (en) 2007-08-16
BRPI0508824A (pt) 2007-08-14
RU2006131599A (ru) 2008-04-27
WO2005089807A3 (en) 2006-09-14
WO2005089807A2 (en) 2005-09-29
AU2005222634A1 (en) 2005-09-29
PE20060077A1 (es) 2006-03-07
CR8620A (es) 2008-01-10
WO2005089808A3 (en) 2006-08-03
EP1725265A2 (en) 2006-11-29
BRPI0508860A (pt) 2007-08-28
CA2557866A1 (en) 2005-09-29
WO2005089808A2 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
PA8626201A1 (es) Conjugados de caliqueamicina
CY1124844T1 (el) Φαρμακευτικο σκευασμα αντισωματος
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
CL2020001333A1 (es) Moléculas de unión b7-h3 novedosas, conjugados anticuerpo-fármaco de los mismos y métodos de uso de los mismos. (divisional solicitud 201802895)
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
CR10273A (es) "anticuerpos anti-5t4 y usos de los mismos"
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
PE20220220A1 (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
CY1119342T1 (el) Τριμερης πρωτεϊνη συντηξης οχ40-ανοσοσφαιρινης και μεθοδοι χρησης
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
AR069747A1 (es) Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
AR050641A1 (es) Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos
SV2007002227A (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
ATE492290T1 (de) Saccharid-konjugatvakzine
CR9742A (es) Proceso para preparar conjugados de anticuerpo y maytansinoide
BR0309868A (pt) Conjugados de derivados de caliqueamicina - veìculo
NO20076046L (no) Bindemidler
CO6241131A2 (es) Vacuna
DOP2023000150A (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos